Apricus Biosciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch APRI and buy or sell other stocks, ETFs, and their options commission-free!

About APRI

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. 

CEO
Raj Mehra, PhD, MBA
CEORaj Mehra, PhD, MBA
Employees
Employees
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1987
Founded1987
Employees
Employees

APRI Key Statistics

Market cap
10.48M
Market cap10.48M
Price-Earnings ratio
-0.08
Price-Earnings ratio-0.08
Dividend yield
Dividend yield
Average volume
334.32K
Average volume334.32K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$49.80
52 Week high$49.80
52 Week low
$0.94
52 Week low$0.94

Stock Snapshot

With a market cap of 10.48M, Apricus Biosciences(APRI) trades at $0.85. The stock has a price-to-earnings ratio of -0.08.

On 2026-07-26, Apricus Biosciences(APRI) stock opened at —, reached a high of —, and a low of —.

Apricus Biosciences(APRI) shares are trading with a volume of 0, against a daily average of 334.32K.

During the past year, Apricus Biosciences(APRI) stock moved between $0.94 at its lowest and $49.80 at its peak.

During the past year, Apricus Biosciences(APRI) stock moved between $0.94 at its lowest and $49.80 at its peak.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.